Browsing by Author "Rezvani, AH"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Thumbnail Image
    ItemOpen Access
    Corrigendum to "Paternal cannabis extract exposure in rats: Preconception timing effects on neurobehavioral effects in offspring" [Neurotoxicology 81 (2020) 180-188].
    (Neurotoxicology, 2021-12) Holloway, Z; Hawkey, AB; Pippen, E; White, H; Katragadda, V; Kenou, B; Wells, C; Murphy, SK; Rezvani, AH; Levin, ED
    The authors regret that the type of cannabis extract provided from the NIDA drug supply program was not the same as was ordered. The authors just recently discovered this. The cannabis extract used in this study provided by the NIDA drug Supply Program was a heated cannabis chemical extract rather than a cannabis smoke extract. The content of delta-9-THC in the extract was the same as reported in the article as verified in chemical analysis of the sample from Research Triangle Institute International (see supplemental material). The authors would like to apologise for any inconvenience caused.
  • Thumbnail Image
    ItemOpen Access
    Different lines of rats selectively-bred for high alcohol-drinking demonstrate disparate preferences for nicotine self-administration
    (Journal of Drug and Alcohol Research, 2016-01-01) Rezvani, AH; Levin, ED; Wells, C; Slade, S; Morrison, M; Marshall, L; Morris, M; Confino, J; Allenby, C; Lumeng, L
    © 2016 Amir H. Rezvani et al.Background. Alcohol and nicotine are commonly coabused. The search for a common core of neural, behavioral, and genetic factors underlying addiction has been the goal of addiction research. Purpose. Genetic predisposition to high alcohol intake has been studied in rats by selectively breeding rats that have high preference for alcohol. The current experiments were conducted to determine if the level of intravenous nicotine administration for the various lines of alcohol-preferring rats differs from that for nonalcohol-preferring controls. Study design. Adult alcohol-naïve selectively-bred alcohol-preferring male rats from four lines (P, AA, HAD-1, sP) and their control nonalcohol-preferring rats (NP, ANA, LAD-1, sNP) were trained and given access to self-administer nicotine (0.03mg/kg/infusion). Results. The results show that the P rats selfadministered significantly more nicotine than NP rats. In contrast, there were no significant differences in nicotine self-administration between the sP and sNP or the AA and ANA rats. Unexpectedly, high alcohol-drinking HAD-1 rats self-administered significantly less nicotine than low alcohol-drinking LAD-1 rats. Conclusion. This suggests that some genetic factors that underlie high-alcohol intake have more general effects in promoting high nicotine intake tendencies, while other genetic factors are more specific to only heavy drinking.
  • Thumbnail Image
    ItemOpen Access
    Risk for opioid abuse is diminished by inhibiting aldehyde dehydrogenase-2 (ALDH-2) in rats
    (Journal of Drug and Alcohol Research, 2019-01-01) Rezvani, AH; Wells, C; Strumph, P; Diamond, I; Blackburn, BK; Levin, ED
    Significant opiate addiction is known to follow prescribed opiate use for pain. There is a serious unmet need for non-addicting medications to prevent subsequent opiate addiction after a short period of opioid treatment for temporary pain. Recent evidence indicates that selective inhibition of aldehyde dehydrogenase-2 (ALDH-2) reduces drug-seeking and trained self-administration of alcohol, cocaine and nicotine, apparently by preventing a concomitant surge of dopamine in the ventral tegmental area (VTA) and nucleus accumbens (NAc). Activation of the same dopaminergic pathway is also implicated in opioid-induced reinforcement. Therefore, we asked whether the selective ALDH-2 inhibitor, ANS-6637, would attenuate opioid self-administration in drug-naïve rats for opioid self-administration. Rats received oral doses of ANS-6637 (9, 18, 36 or 72 mg/kg) or an equal volume of control vehicle 2 h before exposure to remifentanil and a light cue to accentuate self-administration over 5 consecutive days. Self-administration and the numbers of lever presses on both active and inactive levers were recorded. ANS-6637 significantly reduces remifentanil self-administration over 5 sessions of treatment in rats without prior exposure to remifentanil. We also confirm that the highest dose of ANS-6637 (72 mg/kg) used in this study did not prevent remifentanil-induced analgesia using a classic hot plate test. Thus, ANS-6637 significantly reduces of initial exposure to remifentanil self-administration without affecting desired analgesia. These preliminary observations suggest that ANS-6637 appears to have potential value as a non-addictive therapeutic agent to prevent abuse of commonly used opiates in initiating pain management.